π‘ Key Point: Mitral regurgitation (MR) = backward flow of blood from LV β LA during systole.
This leads to LA + LV volume overload, pulmonary congestion, AF, and eventual HF if untreated.
π About
- Definition: Retrograde systolic flow from LV β LA due to incomplete valve closure.
- Acute MR: π¨ Sudden, no time for LA adaptation β pulmonary oedema + acute HF.
- Chronic MR: π°οΈ Gradual; LA dilates & compensates β later LV failure.
𧬠Pathophysiology
- Volume overload: Regurgitant jet β LA pressure & volume β LA dilatation, eccentric LV hypertrophy.
- Acute MR: Sudden rise in LA pressure β pulmonary oedema, cardiogenic shock.
- Chronic MR: Initially well-tolerated β progressive LV dysfunction, HF, AF.
π Causes
- π Mitral Valve Prolapse (MVP): Most common in developed world.
- π Rheumatic Heart Disease: Post-strep scarring & fusion (still common globally).
- β€οΈ Ischaemic Heart Disease: Papillary muscle rupture or dysfunction post-MI.
- π¦ Infective Endocarditis: Leaflet/chordal destruction β acute/chronic MR.
- βοΈ Degenerative Valve Disease: Annular dilatation, calcification.
- π Cardiomyopathy: Dilated/HCM distorts valve apparatus.
- πΆ Congenital: Cleft/parachute valve anomalies.
- 𧬠Connective Tissue: Marfan, Ehlers-Danlos, OI.
- π©Έ Trauma: Papillary/chordal rupture after chest injury.
π©Ί Clinical Features
- Symptoms: Palpitations (AF), exertional dyspnoea, fatigue, orthopnoea/PND if severe.
- Signs:
- πΆ Pansystolic murmur @ apex β axilla.
- π S3 gallop (volume overload).
- Diffuse, displaced apex beat (LV dilatation).
- Soft S1, loud P2 (pulmonary HTN).
- Β± Mid-diastolic rumble if large regurgitant volume.
π§ͺ Investigations
- Bloods: FBC, U&E; cultures if IE suspected.
- ECG: AF, LA enlargement (P mitrale), LVH.
- CXR: LA enlargement, pulmonary oedema, cardiomegaly.
- Echocardiography (TOE best detail): Valve anatomy, regurgitant jet, LA/LV size, pulmonary pressures.
- Cardiac cath: Confirms MR; PCWP shows giant V waves.
βοΈ Management
- π Medical:
β Diuretics β relieve pulmonary congestion.
β ACEi/ARB β reduce afterload.
β Rate control in AF (Ξ²-blockers, digoxin, CaΒ²βΊ blockers).
β Anticoagulation in AF (per CHAβDSβ-VASc).
- π§ Surgical:
β Valve repair preferred (better survival, LV preservation).
β Valve replacement if not repairable (mechanical vs bioprosthetic).
- π©Ή Percutaneous:
β MitraClip for high-risk surgical patients.
β TMVR emerging option.
- β‘ AF Management:
β Rate control, rhythm control, anticoagulation.
- π Monitoring:
β Serial echo (LV function, LA size, pulmonary HTN).
β Clinical: symptoms, functional class.
- π± Lifestyle:
β Moderate exercise.
β Low-salt diet.
β Stop smoking, manage HTN, lipids.
π Teaching Pearl
π‘ Think MR = pansystolic apex murmur β axilla.
π§ Acute MR = pulmonary oedema & shock.
π°οΈ Chronic MR = AF + heart failure later.
Repair > Replace whenever feasible.